Bevacizumab-Based Regimen Improves Progression-Free Survival in HRD-Negative Advanced Ovarian Cancer
A recent report published in Oncology Nursing News highlights the positive impact of a bevacizumab-based regimen on the progression-free survival (PFS) of patients with HRD-negative advanced ovarian cancer. The study demonstrated that the inclusion of bevacizumab, a monoclonal antibody that targets vascular endothelial growth factor (VEGF), significantly improved PFS when combined with standard chemotherapy. HRD-negative ovarian cancer refers to cases where there is no homologous recombination deficiency, which can affect the efficacy of specific treatments. By analyzing data from the phase III GOG-0218 trial, researchers found that patients who received the bevacizumab-containing regimen experienced a longer PFS than those who received standard chemotherapy alone. The findings offer promising prospects for improving HRD-negative advanced ovarian cancer treatment outcomes.